CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Beijing Beilu Pharmaceutical Co Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Beijing Beilu Pharmaceutical Co Ltd
7F, Tower A, Maples International Office
No.32, Xizhimen North St
Phone: +86 1062625287p:+86 1062625287 BEIJING, BEJ  100082  China Ticker: 300016300016
Business Summary
Beijing Beilu Pharmaceutical Co Ltd is a China-based company principally engaged in the research, development, production and sales of chemical drugs (including active pharmaceutical ingredients) and traditional Chinese medicine. The chemical drug business mainly focuses on the research, development, production and sales of contrast agents, hypoglycemic drugs and other products. The traditional Chinese medicine segment mainly focuses on the production and sales of central nervous system, heat-clearing and detoxifying, and tonic products. The Company's main products include gadopentetate dimeglumine injection, iohexol injection, repaglinide tablets, iohexol active pharmaceutical ingredient, Jiuwei Zhenxin Granules, Jinlianhua Granules, Qingwei Huanglian Pills and others. The Company mainly operates its businesses in the domestic and overseas markets.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
2833 Medicinal chemicals and botanical products

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board DaixueWang 64 12/26/2012 2/1/2001
Vice Chairman of the Board XianzhuDuan 53 12/12/2017 12/1/1997
Chief Financial Officer, Director HongLi 62 8/16/2013 2/1/2001
5 additional Officers and Directors records available in full report.

General Information
Number of Employees: 952 (As of 12/31/2023)
Outstanding Shares: 491,946,978 (As of 3/31/2025)
Shareholders: 29,823
Stock Exchange: SHE
Fax Number: +86 1082626933


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, April 17, 2025